Across TCGA pan-cancer cohorts, CD3E mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD3E data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD3E mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD3E expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where CD3E mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.838	0.500	.001	12	view →
PDAC	DFS	Quartile	All	0.424	0.224	.029	8	view →
UCEC	DFS	Median	II,III,IV	0.543	0.919	.048	4	view →
HNSC	OS	Tertile	All	0.779	0.593	.022	2	view →
LSCC	DFS	Quartile	II,III,IV	0.493	0.865	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CD3E tumor-vs-normal RNA expression · all CD3E data types